Answer
Taste disturbances (dysgeusia) occurred in 31.3% of 473 patients with small cell lung cancer receiving IMDYLLTRA (tarlatamab) 10 mg monotherapy in pooled clinical trial data, making them very common (≥1 in 10).
Sources for this answer
- IMDYLLTRA 1 milligram powder for concentrate and solution for solution for infusionAmgen Ltd · emc · SmPC §4.8 Undesirable effects · Version 4Document updated
Sources checked